Latest news
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review - PharmaDispatchPharmaDispatch · Mon, 03 Aug 2026 18:05:21 GMTThe HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants - PharmaDispatchPharmaDispatch · Sun, 02 Aug 2026 15:04:31 GMT